Table 1.

Baseline patient and disease characteristics

ParameterPatients (N = 23)
Median (range) age, y61.0 (27–76)
Male:female, n (%)14 (60.9):9 (39.1)
Race, n (%)
 White18 (78.3)
 Asian3 (13.0)
 Other2 (8.7)
ECOG PS at baseline, n (%)
 011 (47.8)
 112 (52.2)
Measurable disease, n (%)
 Yes21 (91.3)
Primary diagnosis, n (%)
 Pancreatic cancer7 (30.4)
 Chondrosarcoma3 (13.0)
 Adenocarcinoma cervix1 (4.3)
 Basal cell carcinoma1 (4.3)
 Hepatic neoplasm malignant1 (4.3)
 Leiomyosarcoma1 (4.3)
 Malignant fibrous histocytoma1 (4.3)
 Metastatic malignant melanoma1 (4.3)
 Non–small-cell lung cancer1 (4.3)
 Small-cell lung cancer1 (4.3)
 Tongue malignant neoplasm1 (4.3)
 Dermatofibrosarcoma1 (4.3)
 Signet-ring cell carcinoma1 (4.3)
 Primitive neuroendocrine tumor1 (4.3)
 Desmoplastic small round cell tumor1 (4.3)
Prior surgeries, n (%)23 (100.0)
Prior radiotherapy, n (%)
 Yes16 (69.6)
 No7 (30.4)
Prior systemic therapies, n (%)
 Yes21 (91.3)
 No2 (8.7)
Systemic regimens, n (%)
 12 (8.7)
 27 (30.4)
 36 (26.1)
 >36 (26.1)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.